Teva Pharmaceutical Industries (NYSE:TEVA) Given “Neutral” Rating at Credit Suisse Group
Credit Suisse Group reiterated their neutral rating on shares of Teva Pharmaceutical Industries (NYSE:TEVA) in a research note released on Wednesday morning, Briefing.com Automated Import reports.
TEVA has been the subject of a number of other research reports. Zacks Investment Research downgraded shares of Guaranty Federal Bancshares from a hold rating to a sell rating in a research note on Tuesday, April 23rd. Sanford C. Bernstein set a €108.00 ($125.58) target price on shares of Merck KGaA and gave the stock a neutral rating in a research note on Tuesday, June 18th. Bank of America set a $165.00 target price on shares of PVH and gave the stock a buy rating in a research note on Thursday, May 30th. Royal Bank of Canada set a $60.00 target price on shares of Masonite International and gave the stock a buy rating in a research note on Friday, May 3rd. Finally, Maxim Group reissued a hold rating on shares of Arlington Asset Investment in a research note on Thursday, May 2nd. Five research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Teva Pharmaceutical Industries has a consensus rating of Hold and a consensus target price of $15.83.
Shares of TEVA stock traded down $0.21 during trading hours on Wednesday, hitting $8.97. 17,292,732 shares of the company’s stock traded hands, compared to its average volume of 13,789,160. The firm has a 50 day moving average price of $9.17. The stock has a market cap of $9.30 billion, a PE ratio of 3.20, a PEG ratio of 1.13 and a beta of 1.62. Teva Pharmaceutical Industries has a 12 month low of $7.96 and a 12 month high of $25.96. The company has a current ratio of 0.96, a quick ratio of 0.62 and a debt-to-equity ratio of 1.66.
In other news, Director Sol J. Barer purchased 111,000 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were acquired at an average cost of $8.98 per share, for a total transaction of $996,780.00. Following the completion of the acquisition, the director now owns 115,942 shares in the company, valued at $1,041,159.16. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Notaristefani Carlo De sold 16,070 shares of the business’s stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $11.42, for a total transaction of $183,519.40. Following the transaction, the vice president now owns 49,659 shares in the company, valued at $567,105.78. The disclosure for this sale can be found here. 0.49% of the stock is currently owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in TEVA. Cutler Capital Management LLC acquired a new stake in Teva Pharmaceutical Industries during the fourth quarter worth about $2,539,000. Prudential Financial Inc. increased its stake in Teva Pharmaceutical Industries by 105.5% during the fourth quarter. Prudential Financial Inc. now owns 218,134 shares of the company’s stock worth $3,364,000 after acquiring an additional 111,965 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Teva Pharmaceutical Industries by 3.5% during the fourth quarter. Bank of New York Mellon Corp now owns 1,975,038 shares of the company’s stock worth $30,454,000 after acquiring an additional 67,168 shares during the last quarter. Raymond James Financial Services Advisors Inc. increased its stake in Teva Pharmaceutical Industries by 2.0% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 76,187 shares of the company’s stock worth $1,175,000 after acquiring an additional 1,497 shares during the last quarter. Finally, Northern Trust Corp increased its stake in Teva Pharmaceutical Industries by 2.7% during the fourth quarter. Northern Trust Corp now owns 6,687,764 shares of the company’s stock worth $103,125,000 after acquiring an additional 175,173 shares during the last quarter. Institutional investors and hedge funds own 65.08% of the company’s stock.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.